Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)

NCT03902080 is registered in ClinicalTrials.gov with Urovant Sciences GmbH as lead sponsor.

NCT NCT03902080
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03902080 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)
Lead sponsor
Urovant Sciences GmbH
Phase
Phase 3
Overall status
Completed
Start date
March 26, 2019
Completion date
June 15, 2023
Enrollment
1,105 (actual)
Sites
140

Conditions

As the registry lists them; a condition with its own page is linked.

overactive bladder